> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs New Skyrizi Indication
- URL: https://www.fdaweb.com/fda-oks-new-skyrizi-indication/
- Published: 2024-06-20T12:00:00.000Z
- Updated: 2026-09-14T14:33:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157211

FDA has approved a new indication for AbbVie’s Skyrizi (risankizumab-rzaa) to treat moderate to severe ulcerative colitis. The company [says](https://www.prnewswire.com/news-releases/us-fda-approves-skyrizi-risankizumab-rzaa-for-ulcerative-colitis-expanding-abbvies-portfolio-across-inflammatory-bowel-disease-302176163.html?ref=fdaweb.com) the approval was supported by two Phase 3 trials, the INSPIRE 12-week induction trial and the COMMAND 52-week maintenance study.

Skyrizi is described as an interleukin-23 inhibitor. It previously was approved by FDA to treat plaque psoriasis, psoriatic arthritis, and Crohn’s disease.